Get a Free 5ml Mini Now Free 5ml Mini With Every Order of The Mantle
Moumoujus

REPAGERMANIUM.

Insufficient Data CAS 12758-40-6 / SKIN CONDITIONING

Repagermanium, also identified as DMX-200 or propagermanium, is primarily recognized as a pharmaceutical compound under investigation for systemic conditions. In a cosmetic context, it is noted for its potential skin conditioning properties, with observations also suggesting antioxidant effects and immune response modulation.

Summary

skin conditioning antioxidant immune modulator

Science

Mechanism of Action

At a mechanistic level, Repagermanium acts as a C-C chemokine receptor type 2 (CCR2) antagonist, a pathway relevant to inflammatory responses, though its primary study has been in systemic diseases. It has also demonstrated antioxidant capabilities and the ability to modulate immune pathways, such as NF-κB. These properties could hypothetically contribute to reducing skin inflammation and supporting overall skin health, aligning with its listed cosmetic function as 'skin conditioning'.

Research

Clinical Evidence

Low confidence
Effective range N/A
Optimal

N/A

Transparency

Dusting Analysis

Not commonly dusted

No data is available regarding Repagermanium being commonly dusted as a cosmetic ingredient, nor are there established dusting thresholds or red flag percentages in cosmetic applications. Its primary classification as a pharmaceutical drug suggests its use in cosmetics is not yet widespread or well-defined.

The Formula

Formulation

Solubility
Unknown
Optimal pH N/A
0 7 14

Safety

Safety Profile

CIR Status
Not reviewed
Sensitization risk Unknown

Repagermanium is under active development as a pharmaceutical drug for serious conditions such as Focal Segmental Glomerulosclerosis (FSGS), where its brand name QYTOVRA® has received conditional FDA approval. The Cosmetic Ingredient Review (CIR) and the Scientific Committee on Consumer Safety (SCCS) have not assessed Repagermanium for safety in cosmetic applications. While human oral studies as a dietary supplement have reported no negative effects at doses exceeding 1000 mg/day, up to 4.0 g/day, a study involving 30 mg daily for hepatitis B did report adverse events including elevated liver enzymes, languor, and diminished appetite. This background indicates its primary status as a drug and a lack of explicit cosmetic safety evaluation.

Your Skin

Skin Compatibility

No Normal
No Dry
No Oily
No Sensitive
Irritancy Unknown
Comedogenicity Unknown

Our Assessment

Verdict

Insufficient Data

Given its primary classification as a pharmaceutical drug under active investigation and the absence of specific cosmetic safety reviews or clinical efficacy data, there is insufficient information to definitively rate Repagermanium for cosmetic applications.

Related

Similar Ingredients

Finding similar ingredients…